导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.95% | 1505/4773 |
| 近一周 | -0.98% | 1466/5465 |
| 近一月 | -3.48% | 2541/5421 |
| 近一季 | -8.59% | 3339/5231 |
| 近半年 | -4.65% | 2897/4920 |
| 近一年 | 8.19% | 1364/4394 |
| 近两年 | 72.18% | 976/2954 |
| 近三年 | 37.39% | 831/2253 |
| 成立以来 | 83.67% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.71% 1205/4961 |
18.63% 1358/5312 |
- - |
- - |
| 2025 | 30.62% 1304/4813 |
2.16% 1452/3635 |
1.81% 2122/4076 |
24.35% 1479/4524 |
1.00% 1610/4813 |
| 2024 | 6.32% 1772/3463 |
-2.62% 1390/2808 |
-5.23% 1673/3014 |
15.73% 1642/3129 |
-0.46% 1430/3463 |
| 2023 | -6.42% 842/2656 |
7.42% 578/2280 |
-4.18% 1084/2385 |
-4.68% 1201/2515 |
-4.61% 1115/2655 |
| 2022 | -18.03% 652/2207 |
-13.42% 757/1919 |
3.19% 1195/2016 |
-10.46% 408/2113 |
2.48% 923/2208 |
| 2021 | 15.73% 297/1822 |
-1.64% 526/1255 |
9.19% 581/1330 |
4.48% 346/1466 |
3.14% 469/1822 |
| 2020 | 21.32% 692/1250 |
-4.47% 368/1028 |
16.19% 453/1067 |
5.93% 889/1164 |
3.19% 938/1184 |
| 2019 | 25.70% 594/1092 |
30.02% 261/739 |
-9.63% 676/788 |
0.37% 523/850 |
6.59% 584/918 |
| 2018 | - - |
- - |
- - |
- - |
-12.14% 409/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华夏中证500ETF联接C VS. 长安沪深300非周期A(740101) |